A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial) Post author: Post published:May 6, 2026 Post category: Continue ReadingA Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) Post author: Post published:May 6, 2026 Post category: Continue ReadingStudy of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) Post author: Post published:May 6, 2026 Post category: Continue ReadingA Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis Post author: Post published:May 6, 2026 Post category: Continue ReadingEvaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors Post author: Post published:May 6, 2026 Post category: Continue ReadingFT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease Post author: Post published:May 6, 2026 Post category: Continue ReadingA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
CAR-T Cells for HIV Infection Post author: Post published:May 6, 2026 Post category: Continue ReadingCAR-T Cells for HIV Infection
Treatment of Moderate to Severe Refractory Crohn’s Disease Post author: Post published:May 6, 2026 Post category: Continue ReadingTreatment of Moderate to Severe Refractory Crohn’s Disease
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) Post author: Post published:May 6, 2026 Post category: Continue ReadingSafety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus Post author: Post published:May 6, 2026 Post category: Continue ReadingRESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
